France: Thabor Therapeutics, a developer of treatment for patients living with chronic mucosal inflammatory diseases, has secured €2m (US$2.1m) in funding from the French public investment bank Bpifrance, as part of the Deeptech Plan. Funding will support Thabor in its plans to accelerate its R&D programmes and to build upon the industrial development of its…
Home Healthcare Markets International Business Funding round-up: Precision Autoimmune Therapeutics, Jiangsu Huili Biotechnology, Zhiyi Biotech, Vamstar, Thabor...